Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merck
Merck
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters
Mon, 05/13/24 - 11:14 am
Merck
skin cancer
clinical trials
melanoma
vibostolimab
anti-TIGIT
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
Pharma Voice
Fri, 05/10/24 - 11:12 am
Daiichi Sankyo
Enhertu
oncology
Merck
Keytruda strikes out again in endometrial cancer with phase III flop
BioSpace
Thu, 05/9/24 - 11:49 am
Merck
Keytruda
clinical trials
endometrial cancer
How mRNA vaccines could be personalized cancer cures
Axios
Tue, 05/7/24 - 10:59 am
MRNA
vaccines
cancer
personalized medicine
oncology
IO Biotech
Merck
BioNTech
As rival Merck monopolizes BCG supply, ImmunityBio taps Serum Institute for new combo's manufacturing
Fierce Pharma
Mon, 05/6/24 - 11:30 am
Merck
ImmunityBio
BCG
vaccines
bladder cancer
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena
Thu, 05/2/24 - 11:23 am
Merck
Keytruda
gastric cancer
clinical trials
Pfizer takes top spot in docs' vaccine ranking by 'huge margin'
Fierce Pharma
Wed, 05/1/24 - 09:35 am
physicians
vaccines
Pfizer
Merck
GSK
Moderna Therapeutics
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
Fierce Biotech
Mon, 04/29/24 - 10:50 pm
Merck
vaccines
V116
pneumococcal disease
Pfizer
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%
BioSpace
Thu, 04/25/24 - 11:41 am
Merck
earnings
Keytruda
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
Biopharma Reporter
Thu, 04/25/24 - 11:36 am
AstraZeneca
PARP inhibitors
Merck
Lynparza
ovarian cancer
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Fierce Biotech
Thu, 04/18/24 - 11:11 am
M&A
biotech
AstraZeneca
Merck
Gracell
Harpoon Therapeutics
Merck Paid $208 Million to Stop Its Drugs From Working
Motley Fool
Sun, 04/14/24 - 01:27 pm
Merck
M&A
Abceutics
antibody-drug conjugate
With 9% pay hike, Merck CEO Robert Davis entered $20M compensation club in 2023
Fierce Pharma
Sun, 04/14/24 - 01:20 pm
Merck
Pharma CEOs
Robert Davis
executive compensation
AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer
BioSpace
Wed, 04/10/24 - 09:59 am
Merck
Kelun-Biotech
SKB264
gastric cancer
antibody-drug conjugate
clinical trials
AACR
Moderna jumps as vaccine shows benefit in head and neck cancer in early study
Reuters
Tue, 04/9/24 - 05:43 pm
Moderna Therapeutics
Merck
clinical trials
vaccines
head and neck cancer
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS
BioSpace
Fri, 04/5/24 - 11:42 am
Merck
clinical trials
KRAS inhibitors
MK-1084
non-small lung cancer
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
Clinical Trials Arena
Thu, 04/4/24 - 10:53 am
Daiichi Sankyo
Merck
ovarian cancer
clinical trials
raludotatug deruxtecan
R-DXd
'We're open for business': FDA's Peter Marks says agency ready to review novel cancer vaccines despite unknowns
Fierce Biotech
Wed, 04/3/24 - 10:30 pm
Peter Marks
FDA
cancer vaccine
Moderna Therapeutics
Merck
MRNA
mRNA-4157
EU Approves Merck’s Keytruda, Chemo Combo for Lung Cancer
BioSpace
Thu, 03/28/24 - 04:56 pm
Merck
Europe
Keytruda
non-small cell lung cancer
Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair
Fierce Pharma
Wed, 03/27/24 - 11:22 am
Merck
FDA
PAH
Winrevair
sotatercept
Acceleron
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »